Next Article in Journal
Correction: Duan et al. Methionine Restriction Prevents Lipopolysaccharide-Induced Acute Lung Injury via Modulating CSE/H2S Pathway. Nutrients 2022, 14, 322
Previous Article in Journal
Bioactive Peptides from Meretrix lusoria Enzymatic Hydrolysate as a Potential Treatment for Obesity in db/db Mice
Previous Article in Special Issue
Geographical Distribution of Dietary Patterns and Their Association with T2DM in Chinese Adults Aged 45 y and Above: A Nationwide Cross-Sectional Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Nailfold Capillaroscopy: A Comprehensive Review on Its Usefulness in Both Clinical Diagnosis and Improving Unhealthy Dietary Lifestyles

by
Michio Komai
1,*,
Dan Takeno
2,
Chiharu Fujii
2,
Joe Nakano
2,
Yusuke Ohsaki
1 and
Hitoshi Shirakawa
1
1
Laboratory of Nutrition, Graduate School of Agricultural Science, Tohoku University, Sendai 980-8572, Japan
2
At Co., Ltd., Osaka 541-0042, Japan
*
Author to whom correspondence should be addressed.
Nutrients 2024, 16(12), 1914; https://doi.org/10.3390/nu16121914
Submission received: 20 March 2024 / Revised: 16 May 2024 / Accepted: 6 June 2024 / Published: 18 June 2024

Abstract

:
Since the 1970s, the utility of nailfold capillaroscopy (NFC) in diagnosing rheumatological disorders such as systemic sclerosis has been well established. Further studies have also shown that NFC can detect non-rheumatic diseases such as diabetes, glaucoma, dermatitis, and Alzheimer disease. In the past decade, nailfold capillary morphological changes have also been reported as symptoms of unhealthy lifestyle habits such as poor diet, smoking, sleep deprivation, and even psychological stress, all of which contribute to slow blood flow. Therefore, studying the relationships between the morphology of nailfold capillaries and lifestyle habits has a high potential to indicate unhealthy states or even pre-disease conditions. Simple, inexpensive, and non-invasive methods such as NFC are important and useful for routine medical examinations. The present study began with a systematic literature search of the PubMed database followed by a summary of studies reporting the assessment of morphological changes detected by NFC, and a comprehensive review of NFC’s utility in clinical diagnosis and improving unhealthy dietary lifestyles. It culminates in a summary of dietary and lifestyle health promotion strategy, assessed based on NFC and other related measurements that indicate healthy microvascular blood flow and endothelial function.

1. Introduction

Nailfold capillaroscopy (NFC) is a simple, highly sensitive, non-invasive, safe, reliable, and inexpensive tool designed to assess a number of features of nailfold capillaries, including capillary density, blood flow, and different kinds of abnormal morphology. It can provide a visual inspection of the microcirculation in situ. Since the 1970s, NFC has gained recognition in helping to detect diseases that affect the microcirculation, especially many rheumatological disorders, such as connective tissue diseases (CTD) and rheumatic diseases like systemic sclerosis (SSc), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory myositis. Poor lifestyle and dietary habits can cause cardiovascular diseases, Alzheimer’s disease, diabetes, cancer, and other lifestyle-related diseases. A healthy lifestyle, including moderate exercise and the reducing the impact of negative factors such as psychological stress, smoking, and alcoholic intake, can prevent these diseases. Full-length articles published from 1980 to 2023, retrieved from PubMed using the search phrase “nailfold capillaroscopy”, are represented in Figure 1 [1].
The 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for SSc include two (out of the minimum of nine) points towards pathology classification for NFC SSc-specific findings in 2013 ([2], 2013). The inclusion of the NFC evaluation in the SSc classification criteria was based on its role in the early diagnosis of SSc; later the indications for capillaroscopy expanded [3,4,5,6]. Also, standardization guidelines for capillaroscopy practice for Raynaud’s phenomenon (RP) and SSc were recently published by the EULAR Study Group on Microcirculation in Rheumatic Diseases and the Scleroderma Clinical Trials Consortium on Capillaroscopy ([1], 2020).
The usefulness of NFC in the diagnosis of SSc is well known, and in other rheumatic conditions, such as various connective tissue diseases (e.g., vasculitis) and arthritis, nailfold video capillaroscopy (NVC) anomalies are often indicative of a scleroderma-like pattern. However, the utility of NFC in non-rheumatic diseases (NRDs) has not been well studied (for a review over the period of 1990 to 2019, see [7]). Microvascular damage detectable by capillaroscopy is caused by a number of other diseases, including diabetes, glaucoma, dermatology, sickle cell disease (SCD), interstitial lung disease (ILD), idiopathic pulmonary hypertension (i-PAH), Alzheimer’s disease (AD), and Rett syndrome (RS). NFC enables measurements to be evaluated for individual capillaries (length, shape, and diameter of each capillary loop, and the number of capillaries), hemorrhage, the extent of avascular area, angiogenesis, and dynamic parameters (e.g., blood flow velocity, using appropriate software) [8]. Studies published in the last few decades have demonstrated the importance of this innovative technique in the following diseases: diabetes, glaucoma, essential hypertension, psoriasis (dermatology), cardiovascular disease, chronic kidney disease (CKD), and Alzheimer’s disease [9]. One of the papers reviewed concluded that NFC findings (such as reduced capillary density and length, ectatic loops, micro-hemorrhages, tortuosity, dilated capillaries, avascular areas or ramified capillaries, or aneurysms) are not infrequent, even in patients with no underlying CTD. A summary of the included studies with significant differences in NFC findings between controls and patients is provided in [3,9]. These studies conclude that NFC provides key data for the determination of vascular damage in diabetic patients and thus enables the evaluation of disease progression [9], making this technique potentially useful in evaluating microvascular disease. Maldonado and colleagues demonstrated that NFC in patients with diabetes enables the identification of capillaroscopic abnormalities, possibly including a characteristic pattern in this group of patients consisting of cross-linked, tortuous capillaries, ectasias, and avascular zones [10,11]. They also found an association between microangiopathies seen by ophthalmoscopy and the presence of avascular zones and ramified capillaries seen at the nailfold level [10,11].
There have been few studies published on NFC and dietary habits, so in addition to reviewing the utility of NFC measurements, the dietary habit survey was expanded to include microcirculation measurements by other methods. This approach allows for summarizing comments on lifestyle and dietary recommendations for peripheral artery disease (PAD) prevention from the viewpoint of microvascular function and blood flow.

2. Normal Capillaroscopy Pattern in Healthy Subjects

A non-systematic narrative review of the literature in English was conducted using the PubMed database with the aim of undertaking a comprehensive review on the usefulness of NFC, not only in clinical diagnosis, but also in improving unhealthy dietary lifestyles. Emphasis was on the latter category because, to date, there have been few papers published in the ‘healthy subject’ category. The search was developed with the following terms and descriptors: “nailfold capillaroscopy” [Title/Abstract] AND “Humans” [Mesh] AND “last 43 years” [PDat] OR “last 24 years” [PDat]. This search retrieved 327 papers over the last 43 years across all research fields and these were listed in an Excel file. Most papers retrieved were concerned with ‘non-healthy’ subjects. Through inspection of the titles and abstracts for papers from the last 25 years (1999 to 2023), English-written papers with ‘healthy subjects’ were classified according to whether or not they were related to dietary (or nutritional) lifestyle.
A total of 243 original and 84 review articles were identified from 1999 to 2023. Among these, only 14 were concerned with the lifestyle habits of non-patients, among which those concerned with pregnancy were ignored, for a total of only 8 original papers (10 minus 2 pregnancy papers) and no review papers (4 minus 4 pregnancy papers). These papers included not only “randomized controlled trial studies” but also other small-scale pilot studies. Finally, 7 [12,13,14,15,16,17,18] of the 8 original papers were chosen as suitable original articles to cite in the present review, with one sleep quality and duration study excluded [19]. The survey results of recently published NFC papers (1999 to 2023) are summarized in Figure 2.
Dima, A, et al. summarized qualitative NFC assessment in healthy subjects as follows: Most frequently, capillaries stood perpendicular to the nail edge [3,12,20]. The terminal row of capillaries lay parallel to the surface and enabled many features of the capillaries to be observed [12], including their U-shaped ending, which were clearly visible [21]. Under the rows of capillaries, the subpapillary venous plexus could be seen and appeared larger in diameter [22]. The arterial afferent loop is thinner than the venous efferent loop [20]. As well as the hairpin shape, there were two discrete abnormalities and nonspecific variations that were recognized in the normal nailfold: tortuous capillaries (where the loops meandered but did not cross) and crossing capillaries (where the loops crossed once or twice) [1]. Except for these three characteristics (hairpin, tortuous, crossing), all other morphologies were considered abnormal [1]. Ingegnoli, F., et al. defined the morphological characters of the capillaries as hairpin-shaped loops, loops with one cross, loops with more than two intersections, and meandering loops, and proposed three main capillaroscopic patterns for normal variations found in healthy subjects: (1) “Normal” with 2–5 U-shaped loops/mm and a maximum of 2 tortuous loops/mm, (2) “Perfect Normal”, consisting of 5 or more U-shaped loops–/mm, and (3) “Unusual Normal”. The latter was defined as consisting of at least one of the following: one meandering, one bushy loop, one microhemorrhage, or more than 4 crossed loops/mm [23]. Therefore, unusual capillaries might have occurred even in subjects without underlying scleroderma spectrum disorders (SSD) [22]. Counting the number of capillaries per mm was important for defining normality [23]. Different authors have defined various limits for normal capillary density, including 6–14 capillaries/mm [22], 7–10 capillaries/mm [23], 7–12 capillaries [24], 9–13 capillaries/mm [25], and 9–14 (mean 10) capillaries/mm [5]. A recent standardization by the EULAR Study Group for Microcirculation in Rheumatic Diseases defined normal density as 7 or more capillaries/mm [1] (see Table 1).
Similarly, definitions of capillary loop diameter and length varied. Ectasia was initially defined as capillaries with a diameter 4–9 times the normal size, and giant capillaries as more than 10 times larger [20]. Afferent branches were considered to have a normal diameter range of 6–19 µm, and efferent branches of 8–20 µm, with diameters of more than 50 µm defining mega or giant capillaries [20,22,25]. By consensus, it was recently established that a normal capillary diameter should have a maximum diameter of 20 µm and 50 µm for ectasia [1]. Loop length is the visible part of a capillary and were reported by some authors to range from 200–250 µm [22], and reported by others to extend up to 500 µm [23,25]. Elongated capillaries had a length of more than 300 µm, 500 µm, or even 700 µm [26]. Microhemorrhages might have been seen in healthy individuals in cases of local trauma, in which their position was closer to the nail and not related to a recently collapsed giant capillary [20]. The characteristics of NFC morphology in healthy subjects are summarized in Table 2 [12,21,23,25].

3. Nailfold Capillary Patterns Correlate with Age, Gender, Lifestyle Habits

Poor lifestyle and dietary habits can cause cardiovascular diseases [29], cancer [30], diabetes [31], Alzheimer’s disease [32], and other lifestyle-related diseases. A healthy lifestyle, including moderate exercise and reducing psychological stress, smoking, and alcoholic intake, can prevent such diseases. For routine medical examinations, simple, inexpensive, non-invasive methods are preferable. Morphological changes in nailfold capillaries have been reported in patients with unhealthy lifestyle habits such as smoking [13], sleep deprivation, and even psychological stress, all of which can lead to slow blood flow [33]. Therefore, studying the relationships between the morphology of nailfold capillaries and lifestyle habits is likely to provide an indication of an unhealthy state, or even predict the pre-disease condition [14,15]. Several studies have described the normality or normal range of nailfold capillaries in healthy individuals in terms of nailfold capillary morphology [14,15,16,17,23]. Below, four out of seven “non-patient” papers relating to dietary habits, are considered in more detail.

3.1. Example 1: Nailfold Capillaroscopy (NFC) of Healthy Individuals—An Observational Study [14], Table 3

The morphology and capillary density of the nailfold capillaries of healthy individuals were studied and analyzed. It was concluded that a number of capillary morphological features (such as tortuous, dilated, meandering, or bushy capillaries) and decreased plexus visibility can be present in non-clinical individuals with a BMI greater than 25 that was statistically significant (p = 0.0222, in “Plexus” capillary visibility). “Tortuous” capillaries (p = 0.0002) and “Receding” capillaries (p = 0.0229) were more frequently seen in the group of individuals aged more than 41 years (Table 3). They also suggested that these characteristics should be present in the nailfold of three fingers or more for them to be considered pathological.
Table 3. Morphological characteristics of nailfold capillaries present in healthy individuals. (Typical example of NFC, from [14]).
Table 3. Morphological characteristics of nailfold capillaries present in healthy individuals. (Typical example of NFC, from [14]).
Nailfold CapillaryDilatedNeoangiogenesisMeanderingTortuousRamifiedPlexus
Visibility
Micro HemorrhageReceding ***Angulated ****
Male (72)252934294294239
%34.7240.2747.2240.275.5540.275.5531.9412.5
Female (78)2529333962642413
%32.0537.1742.3507.6933.335.1230.7616.66
p0.86240.82470.5490.30260.84420.37970.90740.87680.6244
BMI * < 24.9 (84)3038423653842415
%35.7145.235042.855.9545.234.7628.57117.85
BMI * > 25 (66)202025325174237
%30.330.337.8748.487.5725.756.0634.8410.6
p0.60070.09090.18790.60160.94740.0222 **0.72530.51870.3108
20–40 years (78)2231342333251711
%28.239.7443.5829.483.8441.026.4121.7914.1
41–60 years (72)2827334572333011
%38.8837.545.8362.59.7231.944.6141.6615.27
p0.2250.90920.9110.0002 **0.26540.32540.80740.0229 **0.9699
* BMI = Body Mass Index, ** significant difference, *** to become less clear or less bright, **** having angles or an angular shape. From Gorasiya, AR, et al. [14].

3.2. Example 2: Application of NFC to the Lifestyle Management [15]

Nakajima, T., et al. evaluated the relationship between nailfold capillary morphology, lifestyle habits (particularly those with cardiovascular phenotypes), and coldness of the fingertips, which may indicate a microcirculation disorder suggestive of a pre-disease condition. Their study was undertaken to evaluate the correlation between the morphology of nailfold capillaries and (I) lifestyle habits, (II) clinical experimental design for a broad study, and (III) a follow-up study. In the broad study, both men and women participated and data were collected as fingertip temperatures, images using NFC, and questionnaires about lifestyle habits. In the follow-up study, women participants addressed their improvement in lifestyle habits after the first test, and data were re-analyzed after 1–2 weeks.
Nailfold capillaries were observed under a light microscope (Kekkan-Bijin, AT Co., Ltd., Osaka, Japan; region of observation 500 μm × 700 μm; magnification 320×) after the application of mineral oil to reduce light reflection. Capillary images were captured using a capillary analysis system (CAS; At Co., Ltd., Osaka, Japan). The images of the nailfold capillaries were numerically analyzed for four parameters: diameter, width, length, and distance between the two capillaries. The mean value of these parameters for each individual was used for statistical analysis. The U-shaped area and sums of capillary lengths were measured using a CAS. Representative images of nailfold capillaries showing straight and long loops, twisted or bushy loops, and non-dense and small loops are shown in Figure 3.
They summarized significantly correlated parameters of nailfold capillary morphology and lifestyle habits included in the same group using principal component analysis. In particular, capillary area was negatively correlated with the coldness of fingertips in men aged 20–39 years. Also, capillary width was negatively correlated with sleep problems in men aged 20–39 years, positively correlated with the frequency of smoking in the same group, and negatively correlated with intense exercise in men aged 40 years and over (Figure 4, Lower). In women aged 20–39 years, capillary length was negatively correlated with the frequency of drinking alcohol. Figure 4 (Upper) shows a dot plot indicating a tendency towards smaller lengths of capillary loops in the groups scoring higher for drinking alcohol.
The study by Nakajima, T., et al. could be the first report indicating a correlation between the morphology of nailfold capillaries and lifestyle habits in a non-clinical population involving cardiovascular phenotypes. Therefore, they concluded that the simple, inexpensive, and non-invasive method using NFC can be employed for routine medical examinations everywhere, even at the bedside.

3.3. Example 3: LPS Supplement Improved Capillary Vessel and Blood HbA1c Level [16]

An endotoxin is a lipopolysaccharide on the surface of Gram-negative bacteria causing serious inflammation leading to septicemia. However, LPSs are common in the environment and are not toxic when administered orally or trans-dermally, but they contribute to the activation of innate immunity [34]. In 2017, Nakata, Y., et al. [16] used a dietary supplement containing LPS in a randomized double-blind, parallel-group trial study. The LPS was derived from the Gram-negative bacterium, Pantoea agglomerans (LPSp; containing 201.5 μg/tablet as LPS), and nailfold capillaroscopy measurements were applied to judge the effectiveness of this dietary supplement.
LPS is present in the environment, attaching to edible plants or floating in the air, and it has been recently revealed that the human immune system is influenced by ingesting this environmental LPS, either via diet or the respiratory tract [35]. Since LPS has been found in Chinese medicines and edible plants, Inagawa et al. [36] focused on the physiological actions of naturally ingested LPS and demonstrated its safety and beneficial effects through oral and transdermal administration.
One tablet of this LPSp supplement was composed of 25 mg of fermented wheat extract containing 10 mg/g of LPSp (measured by ELISA (enzyme-linked immunosorbent assay) as 201.5 ± 22.8 μg/tablet). Fifty-two subjects were used in this study including males and females aged 20 to 74. Before the start of the study, all were within the normal range of hematological values (excluding oxidized LDL, IgA, and CRP; mild abnormalities in the “Japan Society of Ningen Dock Criteria”). In the control group (n = 26), the LPSp supplement was replaced with dextrin. They used a CAS (At Co., Ltd., Osaka, Japan) for vascular observation. The capillary vessel and bloodstream in the subungual space of the left ring finger were analyzed microscopically using CAS, and a significant increase was found in the LPSp-supplemented group after three months compared to the control group (Table 4). According to the Japan Diabetes Society (JDS) criteria (https://www.jds.or.jp/modules/en/index.php?content_id=44 (accessed on 19 March 2024)), 24 subjects in the LPSp supplemented group and 20 subjects in the control group were within the borderline range for HbA1c (a glycation marker) at baseline. Including the subjects within the borderline range, a significant decrease in blood HbA1c was found in the LPSp-supplemented group three months after ingestion, indicating an increase in the number of capillary vessels and antiglycative effects associated with oral ingestion of LPSp in healthy subjects.

3.4. Example 4: Fermented Herbal Decoction Improves Peripheral Capillary Morphology [17]

Another example of the effects of dietary factors on nailfold capillary morphology was reported using a fermented herbal decoction by Akazawa-Kudoh, S., et al. in 2018. Reduction in the performance status of the skin condition is one of the serious factors determining the prognosis of post-menopausal women. The purpose of their study was to investigate whether a fermented herbal decoction (FHD) could improve the performance status of post-menopausal skin conditions, by inspecting the capillary conditions in the nailfold in the ring finger of the left hand. A commercially available assortment of 80 wild herbs was prepared and extracted with 100 mL of hot water (98 °C) for 3 min and then roasted dry to obtain 10 g of powder. The resulting extract powder was then fermented for 5 days at 40 °C with Lactobacillus leuteria using a ratio of 100:50:850 of powdered sample/lactobacilli/water (prepared by Echigo Yakusou, Ltd., Niigata, Japan). After centrifugation of the fermentation product at 2000× g for 10 min at room temperature, the resulting supernatant was served as the FHD. A randomized semi-clinical trial was conducted to assess the nailfold capillary length and its age-related value before and after (6 and 12 months) the administration of FHD, which contained γ-amino butyric acid (GABA) produced as part of the fermentation mentioned above. FHD (administered either orally or applied to the skin) improved the performance status of volunteers significantly (p < 0.01), increasing the regeneration of nailfold capillaries (an increase in the number of capillaries reconstituted in the 12-month group). Other dietary supplement-relating papers like Ref. [37] written in Japanese language were excluded from this section.

4. Nailfold Capillaroscopy (NFC) and Its Application for Peripheral Artery Diagnosis

There have been few papers published on NFC and dietary habits, so the dietary habit survey was expanded to include microcirculation measured by other methods and applied to networks of small blood vessels (small arteries, arterioles, capillaries, venules, and small veins). These networks establish a frontier with the interstitium and lymphatic vessels, which aids in maintaining the homeostasis of tissues and the cardiovascular system [38,39,40]. Considered a tissue interstitium, the microcirculation also contributes to the local tissue immune system by allowing the infiltration and adhesion of immune cells [41]. Also, given the small caliber of its components, the microcirculation is a favorable site for the accumulation of hemostatic plugs. From this viewpoint, a summary of the parallel relationship between abnormal NFC data and PAD-related conditions is provided in Table 5.

4.1. Example 1: The Effect of Vitamin D Receptor Activator Treatment on Capillary Blood Velocity (CBV) in Chronic Kidney Disease (CKD) Patients [42]

This paper was included in the present review despite dealing with non-healthy patients with moderate CKD and pre-disease control subjects because of the effectiveness of nutrients on this disease. Previously, Dreyer, G., et al. [46] used ergocalciferol (vitamin D2) in a double-blind randomized trial and showed that vitamin D supplementation improved microvascular endothelial function in the skin, as assessed via laser Doppler flowmetry after iontophoresis of acetylcholine in patients with CKD stages 3–4. Chitalia, N., et al. [47] using cholecalciferol and Zoccali, C., et al. [48] using paricalcitol (a vitamin D receptor activator; VDRA) showed similar results on macrovascular endothelial function, as assessed via determining flow-mediated vasodilatation (FMD) in the brachial artery. The following is a summary of the study by Lundwall, K., et al. [42], who used a double-blind placebo-controlled randomized trial, aiming to investigate whether low- or high-dose treatment with VDRA can ameliorate sympathetic activation and macro- and microvascular functions, as assessed by several state-of-the-art methods in non-diabetic patients with moderate CKD. There was borderline significance (p = 0.05, [16]) for improved capillary blood velocity (CBV), as measured by NFC of the hallux in the treated group 3 months after receiving 2 μg of paricalcitol.

4.2. Example 2: Dynamic Nailfold Videocapillaroscopy May Be Used for Early Microvascular Dysfunction in Obesity [43]

It has been proposed that obesity is the primary cause of microvascular dysfunction, which could be a pathway to increasing blood pressure and decreasing insulin sensitivity. Due to the high global prevalence of this metabolic disorder, Maranhao, et al. investigated which was the most appropriate videocapillaroscopic method (nailfold or dorsal finger) to assess microvascular function in obese patients, since both techniques can be used for both early detection and follow-up. Their results strongly suggest that microvascular dysfunction consequent to obesity could be better detected by dynamic nailfold videocapillaroscopy than by dorsal finger videocapillaroscopy. They speculated that the derangement of microvascular hemodynamics occurs before the diagnosis of hypertension, diabetes, and other metabolic syndromes. Therefore, they advocated that NFC is the most appropriate technique to assess obesity-related microvascular dysfunction as a pre-disease condition.

4.3. Example 3: The Relationship between Nailfold Microcirculation and Retinal Microcirculation in Healthy Subjects [18]

Tian, J., et al. selected 50 subjects without systematic or ocular diseases. The thickness of the peripapillary retinal nerve fiber layer (RNFL), vessel density (VD) of the radial peripapillary capillaries (RPCs), and superficial capillary VD in the macular zone were measured via optical coherence tomography angiography (OCTA) of the left eye. Nailfold microcirculation (including capillary density, avascular zones, dilated capillaries, and hemorrhages) was examined on the fourth digit of each subject’s non-dominant (left) hand via NFC. Lower density nailfold capillaries and abnormalities were found to be associated with reduced RNFL thickness and retinal VD. These results provide a basis for relevant studies on the pathogenesis of ocular diseases with microvascular abnormalities. NFC and OCTA therefore have the potential to identify risk factors and improve the accuracy of early diagnosis and treatment of ocular diseases.

4.4. Example 4: NFC and Peripheral Artery Diseases (PAD) [44]

Studies on NFC patterns and their related predictive value in patients with PAD were rare before 2022. NFC patterns in patients with PAD are likely to be aberrant, so it is suggested that NFC is applicable for assessing patients with PAD in outpatient clinics where NFC patterns are abnormal. Wijnand, J.G.J., et al. recently collected data prospectively on three randomly selected days from patients visiting the outpatient clinic of a single vascular surgery unit for three months in 2018. Eligible patients consenting to the procedure were those with a history of PAD (intermittent claudication, IC; n = 17) or chronic limb-threatening ischemia (CLTI; n = 9). Controls without a history of PAD or CLTI (n = 10) were visitors accompanying the patients.
The results revealed no significant abnormalities in quantitative measures; the mean capillary diameter was within the normal reference value range [21], and the mean capillary count was similar among healthy controls, IC, and CLTI groups. However, among the qualitative measures, the IC group showed prevalence in both the presence of hemorrhages and non-specific qualitative capillary abnormalities (including disturbed architecture, lower density, abnormal morphology, dilatation, areas of decreased vascularity, and atypical branching). Two observations occurred exclusively in CLTI patients, prominent venous plexus (PVP) and mega-capillaries (MCs). These were parallelled by biomarkers of endothelial dysfunction [49]. In systemic sclerosis, the extent of abnormalities revealed by NFC has been linked to circulating biomarkers of inflammation and endothelial dysfunction [50], which have also been shown to be altered in CLTI. These findings suggest that NFC abnormalities may also be used as markers for inflammation and endothelial dysfunction in PAD, although (as both groups noted) confirmation in larger studies is required.

4.5. Example 5: Relationship between NFC Parameters and the Severity of Diabetic Retinopathy [45]

Recently Okabe, et al. investigated whether or not non-invasive measurements with NFC are associated with the presence and severity of diabetic retinopathy (DR) in patients with type 2 diabetes. There were 83 patients with type 2 diabetes and 63 age-matched non-diabetic control subjects. Diabetic patients were classified by the severity of their DR: non-DR (NDR), non-proliferative DR (NPDR), or proliferative DR (PDR). Okabe et al. showed that four NFC parameters in the diabetic patients were significantly lower than in the controls (all p < 0.001); that is, there was a statistically significant decrease in the NFC parameters along with the increasing severity of DR (number: p = 0.02; all others: p < 0.001). Logistic regression analysis revealed that combining the systemic characteristics of age, sex, systolic blood pressure, estimated glomerular filtration rate, Hb A1c level, and history of hypertension or dyslipidemia could indicate the presence of DR or PDR (the area under the receiver operating characteristic curve [AUC] = 0.81, p = 0.006; AUC = 0.87, p = 0.001, respectively). Furthermore, the discriminative power of DR was significantly improved (p = 0.03) by adding NFC length to the systemic findings (AUC = 0.89, p < 0.001). Finally, they concluded that alterations in NFC morphology, such as capillary shortening, may be closely correlated with the presence of DR (diabetic retinopathy) or PDR (proliferative DR).

5. The Role of Dietary or Nutritional Supplementation in Microcirculation

In this final section, the focus is on the role of dietary or nutritional supplementation in microcirculation as summarized from recently published papers, mainly from studies in the USA and the EU where systems for government approval of dietary supplements preceded those of other countries [51].

5.1. Health Claims in the USA and Europe [38]

Food supplements are manufactured from food substances, isolated nutrients, or food-derived compounds, and are available in the form of powders, pills, potions, and other types of medication that are not commonly associated directly with food [52]. Due to the increasing interest shown in personal health, aging demographics, and successful personalized care products, the demand for food supplements has grown and is expected to continue to grow [53]. Cardiovascular disease (CVD) is a significant public health concern worldwide and a leading cause of morbidity and mortality in developed countries [54,55]. In 2015, nearly one-third of all deaths worldwide were caused by CVD according to the World Health Organization [56]. Therefore, the effects of most food supplements on cardiovascular risk and CVD have long since been investigated [53,57,58,59].

5.2. American and European Legal Frameworks for Food Supplements

There are different ways of classifying the claims for the recognition of food supplements in the USA and the EU. In the USA, there are three major categories, namely “nutrition content claims”, “structure/function claims”, and “health claims” [60]. In the EU, the three major categories are “nutrition claims”, “health claims”, and “reduction of disease risk claims” [61]. There is neither a consensus nor overlap between these two different classifications. Indeed, from the scope of the review by Raposo, A., et al. [38], it was deemed adequate to consider only two types of claims, “nutritional claims” (which correspond to the EU “nutrition claims” plus the “nutrition content claims” and “structure/function claims” in the USA) and “health claims” (which encompass the USA “health claims” and “health claims” plus the “reduction of disease risk claims” in the EU).
Authorized health claims approved by the US Food and Drug Administration (FDA) must comply with the Significant Scientific Agreement (SSA) health claims or the FDA Modernization Act (FDAMA) health claims. However, only SSA health claims are allowed on food supplement labels [62]. When a food supplement does not fully satisfy the SSA but is still recognized through some scientific evidence that can support its intended claim, the FDA may recognize that claim as a “qualified health claim”. Thus, it is worth knowing which food supplements may have beneficial effects on the microcirculation by considering that the health claims approved by the USA, the EU, or other governments positively affect consumer choices. Although no health claims were identified directly with the word microcirculation in the list of claims approved by the FDA [62], some of these claims may, in fact, have direct and indirect implications for microcirculation (Table 6). These “Authorized Health Claims” are shown on the left side of this table and “Qualified Health Claims” are shown on the right side of this table.
Regarding the EU [63,64], the list of non-authorized claims with the word ‘microcirculation’ are shown in Table 7, which can be generically considered similar to those recognized by the US FDA. There were five claims with specific references to the word ‘microcirculation’ that were not authorized given the EFSA’s previous assessment [65,66,67,68,69]. This list contained “Dry isoflavones soy extract”, “Niacin”, “Bioflavonoids”, “Vitamin E acetate”, and oligomeric procyanidins. It was described that “Bioflavonoids” have a positive effect on microcirculatory tropism by favoring processes that protect small venous vessels; they protect the body from the harmful action of free radicals and the skin from ultraviolet rays [67]. It was also described that “Vitamin E acetate” supports microcirculation and scalp oxygenation [68].

5.3. Dietary and Lifestyle Recommendation for Peripheral Artery Disease (PAD) Prevention [70] = 2020

PAD is defined as partial or complete stenosis of ≥1 peripheral arteries ([71,72], 2008 and 2015). PAD affects 3–10% of the Western population and if it remains untreated can have devastating consequences for patients and their families. Researchers in Greece, the USA, the UK, and the Netherlands published a review paper entitled “Nutrition, dietary habits, and weight management to prevent and treat patients with PAD” in 2020 [70]. They analyzed how healthy dietary habits can decrease PAD rates when encouraged in the general population, limiting their findings to peripheral arterial disease but excluding patients with aneurysms and arterial diseases also affecting other organs [72]. PAD prevalence ranges between 3–10% in the general population, but can be as high as 15–20% among the elderly [73]. More than 65% of adults with PAD are overweight or obese, while 78% are characterized by deficiencies in vitamins and minerals [74]. Both suboptimal nutritional status and high-fat mass have been associated with the worsening of ambulatory status and vascular health in patients with PAD and claudication [75]. Nutritional advice and weight management are of paramount significance in PAD management [76].
Sagris, M., et al. [70] summarized the dietary and lifestyle recommendations for PAD prevention. They recommended the establishment of regular consumption of various nutrients and fruits, vegetables, and anti-oxidants along with other recommendations for lifestyle management (such as regular physical activity and avoiding smoking). These recommendations include increased consumption of omega-3 fatty acids, various B vitamins (folic acid, B6, B12), fat-soluble vitamins (vitamin A, D, E), vitamin C, and minerals (zinc intake and a sodium upper limit). While further research attempts are anticipated, emphasis on proper nutrition, dietary intervention and weight management should be part of the PAD prevention and treatment as they described [70].

5.4. Advancing beyond the “Heart-Healthy Diet” for PAD [73] = 2015

PAD is a burdensome cardiovascular condition that results from chronic inflammatory insults to the arterial vasculature. Key risk factors include age, gender, type 2 diabetes, hypertension, hypercholesterolemia, hyperhomocysteinemia, smoking, lack of physical exercise, and poor diet, the latter three being modifiable in the development and progression of PAD. A growing body of evidence indicates that imbalanced nutrient intake may contribute to the development and progression of PAD. In 2015, Nosova, E.V., et al. summarized nine categories of nutrients, as well as four diets endorsed by the American Heart Association (AHA) and American College of Cardiology (ACC) that may be prescribed to patients with, or at risk of, PAD [73]. They firstly explained the items of the national “Guidelines for Cardiovascular Disease”. The 2013 AHA/ACC composite Task Force guidelines [77] address nutrition-focused risk reduction strategies for cardiovascular disease in a broad context, with the aim of improving public health. The guidelines endorse a “Heart Healthy Lifestyle” and provide a general framework for incorporating healthy nutrition into lifestyle management to improve blood pressure and lipid control. They emphasize broad nutrient categories associated with better cardiovascular outcomes (e.g., fruits and vegetables, whole grains, legumes, etc.). However, an important limitation is that particular nutrients that may benefit patients with advanced cardiovascular disease have not been explicitly identified. The most specific suggestions are embedded in recommendations for lowering low-density lipoprotein cholesterol (LDL-C); the task force advises obtaining a maximum of 6% of total calories from saturated fat and minimizing intake of foods rich in trans-fatty acids.
The nutrients reviewed by their paper include omega-3 polyunsaturated fatty acids (n-3 PUFAs), B vitamins, and anti-oxidants. The diet plans described include the DASH (Dietary Approaches to Stop Hypertension) diet, Mediterranean diet, low-fat diet, low carbohydrate diet, Dr. Dean Ornish’s Spectrum® Diet, and Dr. Andrew Weil’s Anti-Inflammatory Diet, although the latter two are not recommended by national guidelines [78]. Considering the “Strength of Evidence” from their paper, n-3 PUFAs, fatty fish, and EPA + DHA must be beneficial for primary and secondary prevention of CVD. “Reduce saturated fat intake to 5–6% of total daily caloric intake” and “daily sodium intake restriction to 2.3 g (~6 g/day sodium chloride)” also must be beneficial for the prevention of CVD. “Dietary fiber intake of 14 g/1000 kcal, or 25 g for adult women and 38 g for adult men” are also recommended for CVD prevention. Nosova, E.V., et al. summarized these findings in their paper’s Tables [73] and classified the strength of evidence and level of evidence.

6. The Effects of Dietary Flavonoids on Microvascular Health

Over the past two decades, various experimental and epidemiological studies have shown that the consumption of flavonoid-rich foods is associated with a reduced risk of CVD [79,80]. Flavonoids are a large family of over 5000 hydroxylated polyphenolic compounds that carry out important functions in plants, including attracting pollinating insects, combating environmental stresses such as microbial infection (antifungal activity), and regulating cell growth [81]. Their bioavailability and biological activities in the human body appear to be strongly influenced by their chemical nature.
Vascular function is linked with cognition and brain function, with increased cardiovascular health being associated with greater cognitive performance [82,83,84]. Furthermore, many of the risk factors associated with cardiovascular health are also risk factors for cerebrovascular health, such as hypertension, hypercholesterolemia, and diabetes, with CVD itself having been identified as a risk factor for vascular dementia, caused by a reduction in blood flow to the brain [85,86]. As Rees, A., et al. reported, various flavonoids have significant effects on increasing endothelial function and peripheral blood flow, and thereby on decreasing the risk of CVD [87,88,89,90,91,92]. Rees, A., et al. summarized the effect of flavonoids on endothelial function from the viewpoint of flow-mediated dilation (FMD) measurement. Acute or chronic ingestion of dark chocolate flavanols, chocolate polyphenols, cocoa flavanols, apple polyphenols, and black tea catechins were mostly effective in increasing FMD of peripheral arteries [93,94,95,96,97,98,99,100,101,102,103,104,105,106].

Biological Effects of Epicatechin and Taxifolin [107] = 2021

Bernatova, I. and Liskova, S. emphasized two typical flavonoids: epicatechin and taxifolin. These flavonoids benefit peripheral blood flow and endothelial function. Both are naturally occurring in various fruits, vegetables, and edible tree extracts. Epicatechin is present mainly in green tea, black tea, cacao, and cacao products (cocoa and chocolate). Cacao beans are considered the most abundant source of EC [108,109]. Taxifolin (dihydro-quercetin) can be found in red onions [110], apples [111], tomatoes, sorghum grain, white grapes, strawberries, mulberries [112], acai berries, peanuts, adzuki bean, pine seeds [113], thyme, and citrus fruits [114]. Taxifolin is also present in high concentrations in conifers such as Siberian larch, French maritime bark, Korean red pine, Himalayan cedar, Indian pine, and Chinese yew, from which it can be produced industrially. Both epicatechin and taxifolin are also broadly available in various commercially available food supplements.
The following is a brief summary of examples of the biological effects of (−)-epicatechin as well as (+)-taxifolin and/or (−)-taxifolin demonstrated in experimental models. These effects may be relevant for the treatment of hypertension and viral infections through improvements in peripheral vascular function and anti-inflammatory activity [107]. Reported effects on peripheral vascular function and cardioprotective- and anti-inflammatory effects are summarized in Table 8 [107,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139]. References to the cellular and molecular mechanisms underlying the biological effects of epicatechin and taxifolin are listed in Table 9 [107,115,119,123,128,130,140,141,142,143,144,145,146,147,148,149,150,151,152], including effects on reactive oxygen species (ROS) reduction, activation of anti-oxidant enzymes, endothelial NO elevation, and NF-κB reduction.

7. Conclusions and Prospects

In the past decade, morphological changes in the nailfold capillary have been reported due to the impacts of unhealthy lifestyles such as smoking, inappropriate diets, sleep deprivation, and psychological stress, which lead to slow blood flow. Therefore, the study of the relationships between the morphology of nailfold capillaries and lifestyle habits has a high potential to indicate an unhealthy state, or even to predict a pre-disease condition. Therefore, simple, inexpensive, and non-invasive methods such as NFC are useful for routine medical examinations. This narrative and comprehensive review has examined the usefulness of NFC in both clinical diagnosis and improving unhealthy dietary lifestyles.
Because there is a parallel relationship between abnormal NFC data and PAD-related conditions, this review included a summary of the health claims from recently published papers in the USA and EU (regions where there is a well-developed government-approved dietary supplement system), to provide an overview of the role of dietary or nutritional supplementation in promoting healthy microvascular blood flow and endothelial function.
A strategy for promoting dietary and lifestyle health was summarized based on NFC and other related measurements, focusing on microvascular blood flow and endothelial function. However, dietary interventional research with flavonoids or other functional nutrients is still necessary to fully understand the mechanisms of action of flavonoids and nutrients in the human body, preferably working with pre-symptomatic subjects using NFC monitoring.
Recent research suggests that not only essential nutrients but also flavonoids and other functional food components can exhibit cardio- and neuro-protective beneficial effects, as demonstrated by improvements in both peripheral blood flow and endothelial function.

Author Contributions

Conceptualization, M.K. and D.T.; methodology, D.T., J.N. and C.F.; software, J.N. and C.F.; investigation, M.K., D.T., J.N. and C.F.; resources, M.K. and D.T.; writing—original draft preparation, M.K.; writing—review and editing, D.T., Y.O. and H.S.; supervision, M.K., D.T. and H.S.; project administration, D.T. All authors have read and agreed to the published version of the manuscript.

Funding

This study was partly supported by JSPS KAKENHI Grant-in-Aid for Scientific Research (C) to M.K., Grant Number 23K05108.

Data Availability Statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding authors.

Acknowledgments

The authors thank Nobuyuki Takakura of Osaka University, and other academic members of the Capillary Laboratory and Social Implementation Consortium, for their useful discussions, and also their contribution to the manuscript charge payment. The authors also thank Ian Gleadall for his constructive edition of the English manuscript.

Conflicts of Interest

Authors Dan Takeno, Chiharu Fujii, and Joe Nakano were employed by the company At Co., Ltd., Osaka, Japan. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Smith, V.; Herrick, A.L.; Ingegnoli, F.; Damjanov, N.; De Angelis, R.; Denton, C.P.; Distler, O.; Espejo, K.; Foeldvari, I.; Frech, T.; et al. Standardization of nailfold capillaroscopy for the assessment of patients with Raynaud’s phenomenon and systemic sclerosis. Autoimm. Rev. 2020, 19, 102458. [Google Scholar] [CrossRef]
  2. Van Den Hoogen, F.; Khanna, D.; Franzen, J.; Johnson, S.R.; Baron, M.; Tyndall, A.; Matucci-Cerinic, M.; Naden, R.P.; Medsger, T.A., Jr.; Carreira, P.E.; et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013, 65, 2737–2747. [Google Scholar] [CrossRef]
  3. Dima, A.; Berza, I.; Popescu, D.N.; Parvu, M.I. Nailfold capillaroscopy in systemic diseases: Short overview for internal medicine. Rom. J. Intern. Med. 2021, 59, 201–217. [Google Scholar] [CrossRef]
  4. Cutolo, M. Atlas of Capillaroscopy in Rheumatic Diseases; Elsevier: Amsterdam, The Netherlands, 2010; pp. 25–43. [Google Scholar]
  5. Cutolo, M.; Sullia, A.; Smith, V. How to perform and interpret capillaroscopy. Best Pract. Res. Clin. 2013, 27, 237–248. [Google Scholar] [CrossRef]
  6. Chojnowski, M.M.; Felis-Giemza, A. Olesinska Capillaroscopy—A role in modern rheumatology. Reumatologia 2016, 54, 67–72. [Google Scholar] [CrossRef]
  7. Mansueto, N.; Rotondo, C.; Corrado, A.; Cantatore, F.P. Nailfold capillaroscopy: A comprehensive review on common findings and clinical usefulness in non-rheumatic disease. J. Med. Invest. 2021, 68, 6–14. [Google Scholar] [CrossRef]
  8. Grassi, W.; De Angelis, R. Capillaroscopy: Questions and answers. Clin. Rheumatol. 2009, 26, 2009–2016. [Google Scholar] [CrossRef]
  9. Ciaffi, J.; Nerenxa Ajasllari, N.; Mancarella, L.; Brus, V.; Riccardo Meliconi, R.; Ursini, F. Nailfold capillaroscopy in common non-rheumatic conditions. Microvasc. Res. 2020, 131, 104036. [Google Scholar] [CrossRef]
  10. Maldonado, G.; Rios, C. Nailfold capillaroscopy in diabetes mellitus Potential technique for the microvasculature evaluation. Endocrinol. Metabol. Syndr. 2017, 6, e125. [Google Scholar]
  11. Maldonado, G.; Guerrero, R.; Paredes, C.; Ríos, C. Nailfold capillaroscopy in diabetes mellitus. Microvasc. Res. 2017, 112, 41–46. [Google Scholar] [CrossRef]
  12. Emrani, Z.; Karbalaie, A.; Fatemi, A.; Etehadtavakol, M.; Erlandsson, B.E. Capillary density: An important parameter in nailfold capillaroscopy. Microvasc. Res. 2017, 109, 7–18. [Google Scholar] [CrossRef]
  13. Yuksel, E.P.; Yuksel, S.; Soylu, K.; Aydin, F. Microvascular abnormalities in asymptomatic chronic smokers: A video capillaroscopic study. Microvasc Res. 2019, 124, 51–53. [Google Scholar] [CrossRef]
  14. Gorasiya, A.R.; Mehta, H.H.; Prakashey, A.; Dave, M. Nailfold capillaroscopy of healthy individuals--An observational study. Indian Dermatol. Online J. 2022, 13, 600–605. [Google Scholar] [CrossRef]
  15. Nakajima, T.; Nakano, S.; Kikuchi, A.; Matsunaga, Y. Nailfold capillary patterns correlate with age, gender, lifestyle habits, and fingertip temperature. PLoS ONE 2022, 17, e0269661. [Google Scholar] [CrossRef]
  16. Nakata, Y.; Kohchi, C.; Ogawa, K.; Nakamoto, T.; Yoshimura, H.; Soma, G. Effects of 3 months Continuous intake of supplement containing Pantoea agglomerans LPS to maintain normal bloodstream in adults: Parallel double-blind randomized controlled study. Food Sci. Nutr. 2017, 6, 197–206. [Google Scholar] [CrossRef]
  17. Akazawa-Kudoh, S.; Fujimoto, Y.; Sawada, M.; Takeno, D.; Yamaguchi, N. Fermented Herbal Decoction Improves a Performance Status of Skin Conditions by Reconstituting Peripheral Capillary. E-Cronicon Gynaecol. 2018, 7, 284–292. [Google Scholar]
  18. Tian, J.; Xie, Y.; Li, M.; Oatts, J.; Han, Y.; Yang, Y.; Shi, Y.; Sun, Y.; Sang, J.; Cao, K.; et al. The Relationship Between Nailfold Microcirculation and Retinal Microcirculation in Healthy Subjects. Front. Physiol. 2020, 11, 880. [Google Scholar] [CrossRef]
  19. Bonsen, T.; Wijnstok, N.J.; Hoekstra, T.; Eringa, E.C.; Serne, E.H.; Smulders, Y.M.; Twisk, J.W.R. Sleep quality and duration are related to microvascular function: The Amsterdam Growth and Health Longitudinal Study. J. Sleep Res. 2015, 24, 140–147. [Google Scholar] [CrossRef]
  20. Kayser, C.; Bredemeir, M.; Caleiro, M.T.; Capobianco, K.; Fernandes, T.M.; De Araujo Fontenele, S.M.; Freire, E.; Lonzetti, L.; Miossi, R.; Sekiyama, J.; et al. Position article and guidelines 2018 recommendations of the Brazilian Society of Rheumatology for the indication, interpretation and performance of nailfold capillaroscopy. Adv. Rheumatol. 2019, 59, 1–13. [Google Scholar] [CrossRef]
  21. Tavakol, M.E.; Fatemi, A.; Karbalaie, A.; Emrani, Z.; Erlandsson, B.E. Nailfold capillaroscopy in rheumatic diseases: Which parameters should be evaluated? BioMed Res. Int. 2015, 2015, 974530. [Google Scholar]
  22. Roldán, L.M.C.; Franco, C.J.V.; Navas, M.A.M. Capillaroscopy in systemic sclerosis: A narrative literature review. Rev. Colomb. Reumatol. 2016, 23, 250–258. [Google Scholar]
  23. Ingegnoli, F.; Gualtierotti, R.; Lubatti, C.; Bertolazzi, C.; Gutierrez, M.; Boracchi, P.; Fornili, M.; De Angelis, R. Nailfold capillary patterns in healthy subjects: A real issue in capillaroscopy. Microvasc. Res. 2013, 90, 90–95. [Google Scholar] [CrossRef]
  24. Faggioli, P.; Tamburello, A.; Sciascera, A.; Gilardi, A.G.; Mazzone, A. Nailfold videocapillaroscopy in internal medicine. Ital. J. Med. 2015, 9, 234–242. [Google Scholar] [CrossRef]
  25. Kayser, C.; Sekiyama, J.Y.; Próspero, L.C.; Camargo, C.Z.; Andrade, L.E.C. Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis. Clin. Exp. Rheumatol. 2013, 31 (Suppl. S76), S103–S108. [Google Scholar]
  26. Cutolo, M.; Melsens, K.; Wijnant, S.; Ingegnoli, F.; Thevissen, K.; Keyser, F.D.; Decuman, S.; Müller-Ladner, U.; Piette, Y.; Riccieri, V.; et al. Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal. Autoimmun. Rev. 2018, 17, 344–352. [Google Scholar] [CrossRef]
  27. Ingegnoli, F.; Herrick, A.L. Nailfold capillaroscopy in pediatrics. Arthritis Care Res. 2013, 65, 1393–1400. [Google Scholar] [CrossRef]
  28. Hoerth, C.; Kundi, M.; Katzeschlager, R.; Hirschl, M. Qualitative and quantitative assessment of nailfold capillaries by capillaroscopy in healthy volunteers. Vasa (Eur. J. Vasc. Med.) 2012, 41, 19–26. [Google Scholar] [CrossRef]
  29. Doughty, K.N.; Del Pilar, N.X.; Audette, A.; Katz, D.L. Lifestyle medicine and the management of cardiovascular disease. Curr. Cardiol. Rep. 2017, 19, 116. [Google Scholar] [CrossRef]
  30. Kerschbaum, E.; Nüssler, V. Cancer Prevention with Nutrition and Lifestyle. Visc. Med. 2019, 35, 204–209. [Google Scholar] [CrossRef]
  31. Zheng, Y.; Ley, S.H.; Hu, F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 2018, 14, 88–98. [Google Scholar] [CrossRef]
  32. Kivipelto, M.; Mangialasche, F.; Ngandu, T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat. Rev. Neurol. 2018, 14, 653–666. [Google Scholar] [CrossRef]
  33. Toyoda, M.; Harada, Y.; Masuda, N.; Matsuki, Y.; Urakami, S.; Kobayashi, K. Research on the Relationship Between Blood Flow by Microscope and the Lifestyle Mainly in Female University Students. Proceeding Jissen Women’s Univ. Fac. Hum. Life Sci. 2012, 49, 183–189. [Google Scholar]
  34. Inagawa, H.; Kohchi, C.; Soma, G. Oral administration of lipopolysaccharides for the prevention of various disease: Benefit and usefulness. Anticancer Res. 2011, 31, 2431–2436. [Google Scholar]
  35. Braun-Fahrländer, C.; Riedler, J.; Herz, U.; Eder, W.; Waser, M.; Grize, L.; Maisch, S.; Carr, D.; Gerlach, F.; Bufe, A.; et al. Allergy and Endotoxin Study Team: Environmental exposure to endotoxin and its relation to asthma in school-age children. N. Engl. J. Med. 2002, 347, 869–877. [Google Scholar] [CrossRef]
  36. Inagawa, H.; Nishizawa, T.; Tsukioka, D.; Suda, T.; Chiba, Y.; Okutomi, T.; Morikawa, A.; Soma, G.I.; Mizuno, D. Homeostasis as regulated by activated macrophage. II. LPS of plant origin other than wheat flour and their concomitant bacteria. Chem. Pharm. Bull. 1992, 40, 994–997. [Google Scholar] [CrossRef]
  37. Maeda, Y.; Takeno, D.; Nakano, J.; Fujii, C.; Ukawa, Y.; Shunsuke, I.; Shigehiko, K.; Michiya, I. Investigation of the change in the blood capillaries and the vascular endothelial function during the intake of the pomegranate extract fermented product (URORICH®) containing Urolithin A, observed with a non-invasive capillary microscope. Jpn. Pharmacol. Ther. 2023, 51, 813–829. (In Japanese) [Google Scholar]
  38. Raposo, A.; Saraiva, A.; Ramos, F.; Carrascosa, C.; Raheem, D.; Bárbara, R.; Silva, H. The Role of Food Supplementation in Microcirculation—A Comprehensive Review. Biology 2021, 10, 616, Correction in Biology 2023, 12, 1198. [Google Scholar] [CrossRef] [PubMed]
  39. Guven, G.; Hilty, M.P.; Ince, C. Microcirculation: Physiology, Pathophysiology, and Clinical Application. Blood Purif. 2020, 49, 143–150. [Google Scholar] [CrossRef] [PubMed]
  40. Ince, C.; Mayeux, P.R.; Nguyen, T.; Gomez, H.; Kellum, J.A.; Ospina-Tascón, G.A.; Hernandez, G.; Murray, P.; De Backer, D. The Endothelium in Sepsis. Shock 2016, 45, 259–270. [Google Scholar] [CrossRef]
  41. McCarron, J.G.; Lee, M.D.; Wilson, C. The Endothelium Solves Problems That Endothelial Cells Do Not Know Exist. Trends Pharmacol. Sci. 2017, 38, 322–338. [Google Scholar] [CrossRef]
  42. Lundwall, K.; Jörneskog, G.; Jacobson, S.H.; Spaak, J. Paricalcitol, Microvascular and Endothelial Function in Non-Diabetic Chronic Kidney Disease: A Randomized Trial. Am. J. Nephrol. 2015, 42, 265–273. [Google Scholar] [CrossRef] [PubMed]
  43. Maranhão, P.A.; Coelho de Souza, M.d.G.; Kraemer-Aguiar, L.G.; Bouskela, E. Dynamic nailfold videocapillaroscopy may be used for early microvascular dysfunction in obesity. Microvasc. Res. 2016, 106, 31–35. [Google Scholar] [CrossRef] [PubMed]
  44. Wijnand, J.G.J.; van Rhijn-Brouwer, F.C.C.; Spierings, J.; Teraa, M.; de Borst, G.J.; Verhaar, M.C. Naiflold capillaroscopy in patients with peripheral artery disease of the lower limb (CAPAD Study). Eur. J. Vasc. Endovasc. Surg. 2022, 63, 900–901. [Google Scholar] [CrossRef] [PubMed]
  45. Okabe, T.; Kunikata, H.; Yasuda, M.; Kodama, S.; Maeda, Y.; Nakano, J.; Takeno, D.; Fuse, N.; Nakazawa, T. Relationship between nailfold capillaroscopy parameters and the severity of diabetic retinopathy. Graefe’s Arch. Clinic. Experiment. Ophthalmol. 2024, 262, 759–768. [Google Scholar] [CrossRef] [PubMed]
  46. Dreyer, G.; Tucker, A.T.; Harwood, S.M.; Pearse, R.M.; Raftery, M.J.; Yaqoob, M.M. Ergocalciferol and microcirculatory function in chronic kidney disease and concomitant vitamin D deficiency: An exploratory, double blind, randomised controlled trial. PLoS ONE 2014, 9, e99461. [Google Scholar] [CrossRef] [PubMed]
  47. Chitalia, N.; Ismail, T.; Tooth, L.; Boa, F.; Hampson, G.; Goldsmith, D.; Kaski, J.C.; Banerjee, D. Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS ONE 2014, 9, e91363. [Google Scholar] [CrossRef] [PubMed]
  48. Zoccali, C.; Curatola, G.; Panuccio, V.; Tripepi, R.; Pizzini, P.; Versace, M.; Bolignano, D.; Cutrupi, S.; Politi, R.; Tripepi, G.; et al. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 2014, 64, 1005–1011. [Google Scholar] [CrossRef]
  49. Teraa, M.; Sprengers, R.W.; Westerweel, P.E.; Gremmels, H.; Goumans, M.J.; Teerlink, T.; Moll, F.L.; Verhaar, M.C.; JUVENTAS Study Group. Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. PLoS ONE 2013, 8, e55592. [Google Scholar] [CrossRef]
  50. Avouac, J.; Vallucci, M.; Smith, V. Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. Arthritis Res. Ther. 2013, 15, R55. [Google Scholar] [CrossRef]
  51. Djaoudene, O.; Romano, A.; Bradai, Y.D.; Zebiri, F.; Ouchene, A.; Yousfi, Y.; Amrane-Abider, M.; Sahraoui-Remini, Y.; Madani, K. A Global Overview of Dietary Supplements: Regulation, Market Trends, Usage during the COVID-19 Pandemic, and Health Effects. Nutrients 2023, 15, 3320. [Google Scholar] [CrossRef]
  52. Zeisel, S.H. Regulation of “Nutraceuticals”. Science 1999, 285, 1853–1855. [Google Scholar] [CrossRef] [PubMed]
  53. Bronzato, S.; Durante, A. Dietary Supplements and Cardiovascular Diseases. Int. J. Prev. Med. 2018, 9, 80. [Google Scholar] [PubMed]
  54. Deaton, C.; Froelicher, E.S.; Wu, L.H.; Ho, C.; Shishani, K.; Jaarsma, T. The Global Burden of Cardiovascular Disease. Eur. J. Cardiovasc. Nurs. 2011, 10, S5–S13. [Google Scholar] [CrossRef] [PubMed]
  55. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2095–2128. [Google Scholar] [CrossRef] [PubMed]
  56. World Health Organization. Investing to Overcome the Global Impact of Neglected Tropical Diseases: Third Who Report on Neglected Tropical Diseases 2015; World Health Organization: Geneva, Switzerland, 2015. [Google Scholar]
  57. Baumgartner, S.; Bruckert, E.; Gallo, A.; Plat, J. The position of functional foods and supplements with a serum LDL-C lowering effect in the spectrum ranging from universal to care-related CVD risk management. Atherosclerosis 2020, 311, 116–123. [Google Scholar] [CrossRef] [PubMed]
  58. Vasquez, E.C.; Pereira, T.M.C.; Peotta, V.A.; Baldo, M.P.; Campos-Toimil, M. Review Article Probiotics as Beneficial Dietary Supplements to Prevent and Treat Cardiovascular Diseases: Uncovering Their Impact on Oxidative Stress. Oxidative Med. Cell. Longev. 2019, 2019, 3086270. [Google Scholar] [CrossRef] [PubMed]
  59. Khan, S.U.; Khan, M.U.; Riaz, H.; Valavoor, S.; Zhao, D.; Vaughan, L. Annals of Internal Medicine Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes. Ann. Intern. Med. 2019, 171, 190–198. [Google Scholar] [CrossRef] [PubMed]
  60. FDA. Label Claims for Conventional Foods and Dietary Supplements 2019. Available online: https://www.fda.gov/food/food-labeling-nutrition/label-claims-conventional-foods-and-dietary-supplements (accessed on 19 March 2024).
  61. European Parliament; Council of the European Union. Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. Off. J. Eur. Union 2006, L404, 9–25. [Google Scholar]
  62. Rocha, T.; Amaral, J.S.; Oliveira, M.B.P.P. Adulteration of Dietary Supplements by the Illegal Addition of Synthetic Drugs: A Review. Compr. Rev. Food Sci. Food Saf. 2016, 15, 43–62. [Google Scholar] [CrossRef]
  63. European Commission. Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health. Off. J. Eur. Union 2012, L136, 1–40. [Google Scholar]
  64. Nutrition and Health Claims. EU Register of Nutrition and Health Claims. 2018. Available online: https://ec.europa.eu/food/safety/labelling_nutrition/claims/register/public/?event=register.home (accessed on 19 March 2024).
  65. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to soy isoflavones and protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245), maintenance of normal blood LDL cholesterol concentrations (ID 1135, 1704a, 3093a), reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 3093b, 3154, 3590), maintenance of normal skin tonicity (ID 1704a), contribution to normal hair growth (ID 1704a, 4254), “cardiovascular health” (ID 3587), treatment of prostate cancer (ID 3588) and “upper respiratory tract” (ID 3589) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011, 9, 2264. [Google Scholar]
  66. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to niacin and energy-yielding metabolism (ID 43, 49, 54), function of the nervous system (ID 44, 53), maintenance of the skin and mucous membranes (ID 45, 48, 50, 52), maintenance of normal LDL-cholesterol, HDL cholesterol and triglyceride concentrations (ID 46), maintenance of bone (ID 50), maintenance of teeth (ID 50), maintenance of hair (ID 50, 2875) and maintenance of nails (ID 50, 2875) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2009, 7, 1224. [Google Scholar]
  67. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to: Flavonoids and ascorbic acid in fruit juices, including berry juices (ID 1186); flavonoids from citrus (ID 1471); flavonoids from Citrus paradisi Macfad. (ID 3324, 3325); flavonoids (ID 1470, 1693, 1920); flavonoids in cranberry juice (ID 1804); carotenoids (ID 1496, 1621, 1622, 1796); polyphenols (ID 1636, 1637, 1640, 1641, 1642, 1643); rye bread (ID 1179); protein hydrolysate (ID 1646); carbohydrates with a low/reduced glycaemic load (ID 476, 477, 478, 479, 602) and carbohydrates which induce a low/reduced glycaemic response (ID 727, 1122, 1171); alfalfa (ID 1361, 2585, 2722, 2793); caffeinated carbohydrate-containing energy drinks (ID 1272); and soups (ID 1132, 1133) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011, 9, 2082. [Google Scholar]
  68. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to vitamin E and protection of DNA, proteins and lipids from oxidative damage (ID 160, 162, 1947), maintenance of the normal function of the immune system (ID 161, 163), maintenance of normal bone (ID 164), maintenance of normal teeth (ID 164), maintenance of normal hair (ID 164), maintenance of normal skin (ID 164), maintenance of normal nails (ID 164), maintenance of normal cardiac function (ID 166), maintenance of normal vision by protection of the lens of the eye (ID 167), contribution to normal cognitive function (ID 182, 183), regeneration of the reduced form of vitamin C (ID 203), maintenance of normal blood circulation (ID 216) and maintenance of normal a scalp (ID 2873) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2010, 8, 1816. [Google Scholar]
  69. Globe Newswire. Dietary Supplements Market Size, Share & Trends Analysis Report by Ingredient (Vitamins, Minerals), by Form, by Application, by End User, by Distribution Channel, by Region, and Segment Forecasts, 2020–2027. 2020. Available online: https://www.globenewswire.com/news-release/2020/03/05/1995948/0/en/Dietary-Supplements-Market-Size-Share-Trends-Analysis-Report-by-Ingredient-By-Form-By-Application-By-End-User-By-Distribution-Channel-By-Region-And-Segment-Forecasts-2020-2027.html (accessed on 5 June 2024).
  70. Sagris, M.; Kokkinidis, D.G.; Lempesis, I.G.; Giannopoulos, S.; Rallidis, L.; Mena-Hurtado, C.; Bakoyiannis, C. Nutrition, dietary habits, and weight management to prevent and treat patients with peripheral artery disease. Rev. Cardiovasc. Med. 2020, 21, 565–575. [Google Scholar] [PubMed]
  71. Criqui, M.H.; Aboyans, V. Epidemiology of peripheral artery disease. Circ. Res. 2015, 116, 1509–1526. [Google Scholar] [CrossRef] [PubMed]
  72. Hiatt, W.R.; Goldstone, J.; Smith, S.C., Jr.; McDermott, M.; Moneta, G.; Roberta Oka, R.; Anne B Newman, A.B.; William H Pearce, W.H.; American Heart Association Writing Group 1. Atherosclerotic Peripheral Vascular Disease Symposium II: Nomenclature for vascular diseases. Circulation 2008, 118, 2826–2829. [Google Scholar] [CrossRef] [PubMed]
  73. Nosova, E.V.; Conte, M.S.; Grenon, S.M. Advancing beyond the “heart-healthy diet” for peripheral arterial disease. J. Vascul. Surg. 2015, 61, 265–274. [Google Scholar] [CrossRef]
  74. Thomas, J.; Delaney, C.; Suen, J.; Miller, M. Nutritional status of patients admitted to a metropolitan tertiary care vascular surgery unit. Asia Pac. J. Clin. Nutr. 2019, 28, 64–71. [Google Scholar] [PubMed]
  75. Gardner, A.W.; Bright, B.C.; Ort, K.A.; Montgomery, P.S. Dietary intake of participants with peripheral artery disease and claudication. Angiology 2011, 62, 270–275. [Google Scholar] [CrossRef]
  76. Hirsch, A.T.; Criqui, M.H.; Treat-Jacobson, D.; Regensteiner, J.G.; Creager, M.A.; Olin, J.W.; Krook, S.H.; Hunninghake, D.B.; Comerota, A.J.; Walsh, M.E.; et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286, 1317–1324. [Google Scholar] [CrossRef] [PubMed]
  77. Eckel, R.H.; Jakicic, J.M.; Ard, J.D.; Hubbard, V.S.; de Jesus, J.M.; Lee, I.M.; Lichtenstein, A.H.; Loria, C.M.; Millen, B.E.; Nonas, C.A. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129, S76–S99. [Google Scholar] [CrossRef]
  78. Eilat-Adar, S.; Sinai, T.; Yosefy, C.; Henkin, Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients 2013, 5, 3646–3683. [Google Scholar] [CrossRef] [PubMed]
  79. Rees, A.; Georgina, F.; Dodd, G.F.; Spencer, J.P.E. The Effects of Flavonoids on Cardiovascular Health: A Review of Human Intervention Trials and Implications for Cerebrovascular Function. Nutrients 2018, 10, 1852. [Google Scholar] [CrossRef] [PubMed]
  80. Grassi, D.; Desideri, G.; Croce, G.; Tiberti, S.; Aggio, A.; Ferri, C. Flavonoids, vascular function and cardiovascular protection. Curr. Pharm. Des. 2009, 15, 1072–1084. [Google Scholar] [CrossRef] [PubMed]
  81. Kumar, S.; Pandey, A.K. Chemistry and biological activities of flavonoids: An overview. Sci. World J. 2013, 2013, 162750. [Google Scholar] [CrossRef] [PubMed]
  82. Crichton, G.E.; Elias, M.F.; Davey, A.; Alkerwi, A. Cardiovascular health and cognitive function: The Maine-Syracuse longitudinal study. PLoS ONE 2014, 9, e89317. [Google Scholar] [CrossRef]
  83. Gardener, H.; Wright, C.B.; Dong, C.; Cheung, K.; DeRosa, J.; Nannery, M.; Stern, Y.; Elkind, M.S.; Sacco, R.L. Ideal cardiovascular health and cognitive aging in the northern Manhattan study. J. Am. Heart Assoc. 2016, 5, e002731. [Google Scholar] [CrossRef]
  84. Samieri, C.; Perier, M.C.; Gaye, B.; Proust-Lima, C.; Helmer, C.; Dartigues, J.F.; Berr, C.; Tzourio, C.; Empana, J.P. Association of cardiovascular health level in older age with cognitive decline and incident dementia. JAMA 2018, 320, 657–664. [Google Scholar] [CrossRef] [PubMed]
  85. Knopman, D.; Boland, L.L.; Mosley, T.; Howard, G.; Liao, D.; Szklo, M.; McGovern, P.; Folsom, A.R. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56, 42–48. [Google Scholar] [CrossRef]
  86. Vicario, A.; Cerezo, G.H. At the heart of brain disorders—Preventing cognitive decline and dementia. Eur. Cardiol. Rev. 2015, 10, 60–63. [Google Scholar] [CrossRef]
  87. McCullough, M.L.; Peterson, J.J.; Patel, R.; Jacques, P.F.; Shah, R.; Dwyer, J.T. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of us adults. Am. J. Clin. Nutr. 2012, 95, 454–464. [Google Scholar] [CrossRef] [PubMed]
  88. Mink, P.J.; Scrafford, C.G.; Barraj, L.M.; Harnack, L.; Hong, C.P.; Nettleton, J.A.; Jacobs, D.R., Jr. Flavonoid intake and cardiovascular disease mortality: A prospective study in postmenopausal women. Am. J. Clin. Nutr. 2007, 85, 895–909. [Google Scholar] [CrossRef]
  89. Wang, X.; Ouyang, Y.Y.; Liu, J.; Zhao, G. Flavonoid intake and risk of cvd: A systematic review and meta-analysis of prospective cohort studies. Br. J. Nutr. 2014, 111, 1–11. [Google Scholar] [CrossRef]
  90. Cassidy, A.; O’Reilly, E.J.; Kay, C.; Sampson, L.; Franz, M.; Forman, J.P.; Curhan, G.; Rimm, E.B. Habitual intake of flavonoid subclasses and incident hypertension in adults. Am. J. Clin. Nutr. 2011, 93, 338–347. [Google Scholar] [CrossRef]
  91. Mursu, J.; Voutilainen, S.; Nurmi, T.; Tuomainen, T.P.; Kurl, S.; Salonen, J.T. Flavonoid intake and the risk of ischaemic stroke and cvd mortality in middle-aged Finnish men: The kuopio ischaemic heart disease risk factor study. Br. J. Nutr. 2008, 100, 890–895. [Google Scholar] [CrossRef] [PubMed]
  92. Peterson, J.J.; Dwyer, J.T.; Jacques, P.F.; McCullough, M.L. Associations between flavonoids and cardiovascular disease incidence or mortality in European and us populations. Nutr. Rev. 2012, 70, 491–508. [Google Scholar] [CrossRef] [PubMed]
  93. Sansone, R.; Rodriguez-Mateos, A.; Heuel, J.; Falk, D.; Schuler, D.; Wagstaff, R.; Kuhnle, G.G.; Spencer, J.P.; Schroeter, H.; Merx, M.W.; et al. Cocoa flavanol intake improves endothelial function and framingham risk score in healthy men and women: A randomised, controlled, double-masked trial: The flaviola health study. Br. J. Nutr. 2015, 114, 1246–1255. [Google Scholar] [CrossRef]
  94. Faridi, Z.; Njike, V.Y.; Dutta, S.; Ali, A.; Katz, D.L. Acute dark chocolate and cocoa ingestion and endothelial function: A randomized controlled crossover trial. Am. J. Clin. Nut. 2008, 88, 58–63. [Google Scholar] [CrossRef]
  95. Engler, M.B.; Engler, M.M.; Chen, C.Y.; Malloy, M.J.; Browne, A.; Chiu, E.Y.; Kwak, H.K.; Milbury, P.; Paul, S.M.; Blumberg, J.; et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J. Am. Coll. Nutr. 2004, 23, 197–204. [Google Scholar] [CrossRef]
  96. Dower, J.I.; Geleijnse, J.M.; Kroon, P.A.; Philo, M.; Mensink, M.; Kromhout, D.; Hollman, P.C. Does epicatechin contribute to the acute vascular function effects of dark chocolate? A randomized, crossover study. Mol. Nutr. Food Res. 2016, 60, 2379–2386. [Google Scholar] [CrossRef] [PubMed]
  97. Fisher, N.D.; Hollenberg, N.K. Aging and vascular responses to flavanol-rich cocoa. J. Hypertens. 2006, 24, 1575–1580. [Google Scholar] [CrossRef] [PubMed]
  98. Bondonno, C.P.; Yang, X.; Croft, K.D.; Considine, M.J.; Ward, N.C.; Rich, L.; Puddey, I.B.; Swinny, E.; Mubarak, A.; Hodgson, J.M. Flavonoid-rich apples and nitrate-rich spinach augment nitric oxide status and improve endothelial function in healthy men and women: A randomized controlled trial. Free Radic. Biol. Med. 2012, 52, 95–102. [Google Scholar] [CrossRef] [PubMed]
  99. Bondonno, N.P.; Bondonno, C.P.; Blekkenhorst, L.C.; Considine, M.J.; Maghzal, G.; Stocker, R.; Woodman, R.J.; Ward, N.C.; Hodgson, J.M.; Croft, K.D. Flavonoid-rich apple improves endothelial function in individuals at risk for cardiovascular disease: A randomized controlled clinical trial. Mol. Nutr. Food Res. 2017, 62, 1700674. [Google Scholar] [CrossRef] [PubMed]
  100. Grassi, D.; Mulder, T.P.; Draijer, R.; Desideri, G.; Molhuizen, H.O.; Ferri, C. Black tea consumption dose-dependently improves flow-mediated dilation in healthy males. J. Hypertens. 2009, 27, 774–781. [Google Scholar] [CrossRef] [PubMed]
  101. Schreuder, T.H.; Eijsvogels, T.M.; Greyling, A.; Draijer, R.; Hopman, M.T.; Thijssen, D.H. Effect of black tea consumption on brachial artery flow-mediated dilation and ischaemia-reperfusion in humans. Appl. Physiol. Nutr. Metab. 2014, 39, 145–151. [Google Scholar] [CrossRef] [PubMed]
  102. Schroeter, H.; Heiss, C.; Balzer, J.; Kleinbongard, P.; Keen, C.L.; Hollenberg, N.K.; Sies, H.; Kwik-Uribe, C.; Schmitz, H.H.; Kelm, M. (-)-epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc. Natl. Acad. Sci. USA 2006, 103, 1024–1029. [Google Scholar] [CrossRef] [PubMed]
  103. Marsh, C.E.; Carter, H.H.; Guelfi, K.J.; Smith, K.J.; Pike, K.E.; Naylor, L.H.; Green, D.J. Brachial and cerebrovascular functions are enhanced in postmenopausal women after ingestion of chocolate with a high concentration of cocoa. J. Nutr. 2017, 147, 1686–1692. [Google Scholar] [CrossRef]
  104. Jochmann, N.; Lorenz, M.; Krosigk, A.; Martus, P.; Bohm, V.; Baumann, G.; Stangl, K.; Stangl, V. The efficacy of black tea in ameliorating endothelial function is equivalent to that of green tea. Br. J. Nutr. 2008, 99, 863–868. [Google Scholar] [CrossRef]
  105. Duffy, S.J.; Keaney, J.F., Jr.; Holbrook, M.; Gokce, N.; Swerdloff, P.L.; Frei, B.; Vita, J.A. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001, 104, 151–156. [Google Scholar] [CrossRef]
  106. Grassi, D.; Draijer, R.; Schalkwijk, C.; Desideri, G.; D’Angeli, A.; Francavilla, S.; Mulder, T.; Ferri, C. Black tea increases circulating endothelial progenitor cells and improves flow mediated dilatation counteracting deleterious effects from a fat load in hypertensive patients: A randomized controlled study. Nutrients 2016, 8, 727. [Google Scholar] [CrossRef] [PubMed]
  107. Bernatova, I.; Liskova, S. Mechanisms modified by (-)-epicatechin and taxifolin relevant for the treatment of hypertension and viral infection: Knowledge from preclinical studies. Antioxidants 2021, 10, 467. [Google Scholar] [CrossRef] [PubMed]
  108. Miller, K.B.; Hurst, W.J.; Flannigan, N.; Ou, B.; Lee, C.Y.; Smith, N.; Stuart, D.A. Survey of commercially available chocolate- and cocoa-containing products in the United States. 2. Comparison of flavan-3-ol content with nonfat cocoa solids, total polyphenols, and percent cacao. J. Agric. Food Chem. 2009, 57, 9169–9180. [Google Scholar] [CrossRef] [PubMed]
  109. Alanon, M.E.; Castle, S.M.; Siswanto, P.J.; Cifuentes-Gomez, T.; Spencer, J.P. Assessment of flavanol stereoisomers and caffeine and theobromine content in commercial chocolates. Food Chem. 2016, 208, 177–184. [Google Scholar] [CrossRef]
  110. Slimestad, R.; Fossen, T.; Vågen, I.M. Onions: A source of unique dietary flavonoids. J. Agric. Food Chem. 2007, 55, 10067–10080. [Google Scholar] [CrossRef]
  111. Vega-Villa, K.R.; Remsberg, C.M.; Takemoto, J.K.; Ohgami, Y.; Yáñez, J.A.; Andrews, P.K.; Davies, N.M. Stereospecific pharmacokinetics of racemic homoeriodictyol, isosakuranetin, and taxifolin in rats and their disposition in fruit. Chirality 2011, 23, 339–348. [Google Scholar] [CrossRef]
  112. Zhang, W.; Han, F.; He, J.; Duan, C. HPLC-DAD-ESI-MS/MS analysis and antioxidant activities of nonanthocyanin phenolics in mulberry (Morus alba L.). J. Food Sci. 2008, 73, C512–C518. [Google Scholar] [CrossRef]
  113. Lantto, T.A.; Dorman, H.J.D.; Shikov, A.N.; Pozharitskaya, O.N.; Makarov, V.G.; Tikhonov, V.P.; Hiltunen, R.; Raasmaja, A. Chemical composition, antioxidative activity and cell viability effects of a Siberian pine (Pinus sibirica Du Tour) extract. Food Chem. 2009, 112, 936–943. [Google Scholar] [CrossRef]
  114. Gerhäuser, C. Beer constituents as potential cancer chemopreventive agents. Eur. J. Cancer 2005, 41, 1941–1954. [Google Scholar] [CrossRef] [PubMed]
  115. Kluknavsky, M.; Balis, P.; Puzserova, A.; Radosinska, J.; Berenyiova, A.; Drobna, M.; Lukac, S.; Muchova, J.; Bernatova, I. (−)-Epicatechin prevents blood pressure increase and reduces locomotor hyperactivity in young spontaneously hypertensive rats. Oxidative Med. Cell. Longev. 2016, 2016, 6949020. [Google Scholar] [CrossRef]
  116. Garate-Carrillo, A.; Navarrete-Yañez, V.; Ortiz-Vilchis, P.; Guevara, G.; Castillo, C.; Mendoza-Lorenzo, P.; Ceballos, G.; Ortiz-Flores, M.; Najera, N.; Bustamante-Pozo, M.M.; et al. Arginase inhibition by (−)-epicatechin reverses endothelial cell aging. Eur. J. Pharmacol. 2020, 885, 173442. [Google Scholar] [CrossRef]
  117. Galleano, M.; Bernatova, I.; Puzserova, A.; Balis, P.; Sestakova, N.; Pechanova, O.; Fraga, C.G. (−)-Epicatechin reduces blood pressure and improves vasorelaxation in spontaneously hypertensive rats by NO-mediated mechanism. IUBMB Life 2013, 65, 710–715. [Google Scholar] [CrossRef] [PubMed]
  118. Aggio, A.; Grassi, D.; Onori, E.; D’Alessandro, A.; Masedu, F.; Valenti, M.; Ferri, C. Endothelium/nitric oxide mechanism mediates vasorelaxation and counteracts vasoconstriction induced by low concentration of flavanols. Eur. J. Nutr. 2013, 52, 263–272. [Google Scholar] [CrossRef] [PubMed]
  119. MacRae, K.; Connolly, K.; Vella, R.; Fenning, A. Epicatechin’s cardiovascular protective effects are mediated via opioid receptors and nitric oxide. Eur. J. Nutr. 2019, 58, 515–527. [Google Scholar] [CrossRef]
  120. Novakovic, A.; Marinko, M.; Vranic, A.; Jankovic, G.; Milojevic, P.; Stojanovic, I.; Nenezic, D.; Ugresic, N.; Kanjuh, V.; Yang, Q.; et al. Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (−)-epicatechin. Eur. J. Pharmacol. 2015, 762, 306–312. [Google Scholar] [CrossRef] [PubMed]
  121. Marinko, M.; Jankovic, G.; Nenezic, D.; Milojevic, P.; Stojanovic, I.; Kanjuh, V.; Novakovic, A. (−)-Epicatechin-induced relaxation of isolated human saphenous vein: Roles of K+ and Ca2+ channels. Phytother. Res. 2018, 32, 267–275. [Google Scholar] [CrossRef]
  122. Plotnikov, M.B.; Aliev, O.I.; Sidekhmenova, A.V.; Shamanaev, A.Y.; Anishchenko, A.M.; Fomina, T.I.; Chernysheva, G.A.; Smol’yakova, V.I.; Arkhipov, A.M. Dihydroquercetin improves microvascularization and microcirculation in the brain cortex of SHR rats during the development of arterial hypertension. Bull. Exp. Biol. Med. 2017, 163, 57–60. [Google Scholar] [CrossRef]
  123. Kwak, C.J.; Kubo, E.; Fujii, K.; Nishimura, Y.; Kobuchi, S.; Ohkita, M.; Yoshimura, M.; Kiso, Y.; Matsumura, Y. Antihypertensive effect of French maritime pine bark extract (Flavangenol): Possible involvement of endothelial nitric oxide-dependent vasorelaxation. J. Hypertens. 2009, 27, 92–101. [Google Scholar] [CrossRef]
  124. Shah, Z.A.; Li, R.C.; Ahmad, A.S.; Kensler, T.W.; Yamamoto, M.; Biswal, S.; Doré, S. The flavanol (−)-epicatechin prevents stroke damage through the Nrf2/HO1 pathway. J. Cereb. Blood Flow Metab. 2010, 30, 1951–1961. [Google Scholar] [CrossRef]
  125. Calabró, V.; Piotrkowski, B.; Fischerman, L.; Vazquez Prieto, M.A.; Galleano, M.; Fraga, C.G. Modifications in nitric oxide and superoxide anion metabolism induced by fructose overload in rat heart are prevented by (−)-epicatechin. Food Funct. 2016, 7, 1876–1883. [Google Scholar] [CrossRef]
  126. Yamazaki, K.G.; Taub, P.R.; Barraza-Hidalgo, M.; Rivas, M.M.; Zambon, A.C.; Ceballos, G.; Villarreal, F.J. Effects of (−)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion. J. Am. Coll. Cardiol. 2010, 55, 2869–2876. [Google Scholar] [CrossRef]
  127. Guo, Y.; Wang, T.; Fu, F.F.; El-Kassaby, Y.A.; Wang, G. Temporospatial flavonoids metabolism variation in Ginkgo biloba leaves. Front. Genet. 2020, 11, 1503. [Google Scholar] [CrossRef] [PubMed]
  128. Shu, Z.; Yang, Y.; Yang, L.; Jiang, H.; Yu, X.; Wang, Y. Cardioprotective effects of dihydroquercetin against ischemia reperfusion injury by inhibiting oxidative stress and endoplasmic reticulum stress-induced apoptosis via the PI3K/Akt pathway. Food Funct. 2019, 10, 203–215. [Google Scholar] [CrossRef] [PubMed]
  129. Vasconcelos, P.C.D.P.; Seito, L.N.; Di Stasi, L.C.; Akiko Hiruma-Lima, C.; Pellizzon, C.H. Epicatechin used in the treatment of intestinal inflammatory disease: An analysis by experimental models. Evid. Based Complement. Alternat. Med. 2012, 2012, 508902. [Google Scholar] [CrossRef] [PubMed]
  130. Prince, P.D.; Fischerman, L.; Toblli, J.E.; Fraga, C.G.; Galleano, M. LPS-induced renal inflammation is prevented by (−)-epicatechin in rats. Redox Biol. 2017, 11, 342–349. [Google Scholar] [CrossRef] [PubMed]
  131. Kang, J.; Wang, Z.; Oteiza, P.I. (−)-Epicatechin mitigates high fat diet-induced neuroinflammation and altered behavior in mice. Food Funct. 2020, 11, 5065–5076. [Google Scholar] [CrossRef] [PubMed]
  132. Inoue, T.; Saito, S.; Tanaka, M.; Yamakage, H.; Kusakabe, T.; Shimatsu, A.; Ihara, M.; Satoh-Asahara, N. Pleiotropic neuroprotective effects of taxifolin in cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. USA 2019, 116, 10031–10038. [Google Scholar] [CrossRef] [PubMed]
  133. Zeng, Y.; Song, J.; Zhang, M.; Wang, H.; Zhang, Y.; Suo, H. Comparison of in vitro and in vivo antioxidant activities of six flavonoids with similar structures. Antioxidants 2020, 9, 732. [Google Scholar] [CrossRef] [PubMed]
  134. Sinegre, T.; Teissandier, D.; Milenkovic, D.; Morand, C.; Lebreton, A. Epicatechin influences primary hemostasis, coagulation and fibrinolysis. Food Funct. 2019, 10, 7291–7298. [Google Scholar] [CrossRef] [PubMed]
  135. Sinegre, T.; Milenkovic, D.; Bourgne, C.; Teissandier, D.; Nasri, Y.; Dannus, L.T.; Morand, C.; Lebreton, A. Impact of epicatechin on the procoagulant activities of microparticles. Nutrients 2020, 12, 2935. [Google Scholar] [CrossRef]
  136. Plotnikov, M.B.; Aliev, O.I.; Sidekhmenova, A.V.; Shamanaev, A.Y.; Anishchenko, A.M.; Nosarev, A.V.; Pushkina, E.A. Modes of hypotensive action of dihydroquercetin in arterial hypertension. Bull. Exp. Biol. Med. 2017, 162, 353–356. [Google Scholar]
  137. Kubatiev, A.A.; Yadigarova, Z.T.; Rud’ko, I.A.; Tyukavkina, N.A.; Bykov, V.A. Diquertin suppresses ADP- and thrombin-induced accumulation of cytoplasmic calcium in human thrombocytes. Pharm. Chem. J. 1999, 33, 629–630. [Google Scholar] [CrossRef]
  138. Ivanov, I.S.; Sidehmenova, A.V.; Smol’yakova, V.I.; Chernysheva, G.A.; Plotnikov, M.B. Inhibition of adenosine diphosphate-induced platelet aggregation by alpha-lipoic acid and dihydroquercetin in vitro. Indian J. Pharmacol. 2014, 46, 430–432. [Google Scholar] [PubMed]
  139. Chen, Y.; Deuster, P. Comparison of quercetin and dihydroquercetin: Antioxidant-independent actions on erythrocyte and platelet membrane. Chem. Biol. Interact. 2009, 182, 7–12. [Google Scholar] [CrossRef] [PubMed]
  140. Ruijters, E.J.; Weseler, A.R.; Kicken, C.; Haenen, G.R.; Bast, A. The flavanol (−)-epicatechin and its metabolites protect against oxidative stress in primary endothelial cells via a direct antioxidant effect. Eur. J. Pharmacol. 2013, 715, 147–153. [Google Scholar] [CrossRef] [PubMed]
  141. Kostyuk, V.A.; Potapovich, A.I.; Strigunova, E.N.; Kostyuk, T.V.; Afanas’ev, I.B. Experimental evidence that flavonoid metal complexes may act as mimics of superoxide dismutase. Arch. Biochem. Biophys. 2004, 428, 204–208. [Google Scholar] [CrossRef] [PubMed]
  142. Shubina, V.S.; Shatalin, Y.V. Antioxidant and iron-chelating properties of taxifolin and its condensation product with glyoxylic acid. J. Food Sci. Technol. 2017, 54, 1467–1475. [Google Scholar] [CrossRef] [PubMed]
  143. Gómez-Guzmán, M.; Jiménez, R.; Sánchez, M.; Romero, M.; O’Valle, F.; Lopez-Sepulveda, R.; Quintela, A.M.; Galindo, P.; Zarzuelo, M.J.; Bailón, E.; et al. Chronic (−)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats. Br. J. Nutr. 2011, 106, 1337–1348. [Google Scholar] [CrossRef] [PubMed]
  144. Prince, P.D.; Fraga, C.G.; Galleano, M. (−)-Epicatechin administration protects kidneys against modifications induced by short-term l-NAME treatment in rats. Food Funct. 2020, 11, 318–327. [Google Scholar] [CrossRef]
  145. Sakuma, S.; Kishiwaki, Y.; Matsumura, M.; Sawada, H.; Hashimoto, R.; Gotoh, K.; Umemoto, K.; Fujimoto, Y. Taxifolin Potently Diminishes Levels of Reactive Oxygen Species in Living Cells Possibly by Scavenging Peroxyl Radicals. Am. J. Pharmacol. Toxicol. 2018, 13, 1–6. [Google Scholar] [CrossRef]
  146. Gómez-Guzmán, M.; Jiménez, R.; Sánchez, M.; Zarzuelo, M.J.; Galindo, P.; Quintela, A.M.; López-Sepulveda, R.; Romero, M.; Tamargo, J.; Vargas, F.; et al. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic. Biol. Med. 2012, 52, 70–79. [Google Scholar] [CrossRef]
  147. Prince, P.D.; Lanzi, C.R.; Toblli, J.E.; Elesgaray, R.; Oteiza, P.I.; Fraga, C.G.; Galleano, M. Dietary (−)-epicatechin mitigates oxidative stress, NO metabolism alterations, and inflammation in renal cortex from fructose-fed rats. Free Radic. Biol. Med. 2015, 90, 35–46. [Google Scholar] [CrossRef] [PubMed]
  148. Morrison, M.; Van der Heijden, R.; Heeringa, P.; Kaijzel, E.; Verschuren, L.; Blomhoff, R.; Kooistra, T.; Kleemann, R. Epicatechin attenuates atherosclerosis and exerts anti-inflammatory effects on diet-induced human-CRP and NF-kB in vivo. Atherosclerosis 2014, 233, 149–156. [Google Scholar] [CrossRef] [PubMed]
  149. Prince, P.D.; Rodríguez Lanzi, C.; Fraga, C.G.; Galleano, M. Dietary (−)-epicatechin affects NF-κB activation and NADPH oxidases in the kidney cortex of high-fructose-fed rats. Food Funct. 2019, 10, 26–32. [Google Scholar] [CrossRef] [PubMed]
  150. Wang, Y.-H.; Wang, W.-Y.; Chang, C.-C.; Liou, K.-T.; Sung, Y.-J.; Liao, J.-F.; Chen, C.-F.; Chang, S.; Hou, Y.-C.; Chou, Y.-C.; et al. Taxifolin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kB activation. J. Biomed. Sci. 2006, 13, 127–141. [Google Scholar] [CrossRef] [PubMed]
  151. Ding, T.; Wang, S.; Zhang, X.; Zai, W.; Fan, J.; Chen, W.; Bian, Q.; Luan, J.; Shen, Y.; Zhang, Y.; et al. Kidney protection effects of dihydroquercetin on diabetic nephropathy through suppressing ROS and NLRP3 inflammasome. Phytomedicine 2018, 41, 45–53. [Google Scholar] [CrossRef]
  152. Ye, Y.; Wang, X.; Cai, Q.; Zhuang, J.; Tan, X.; He, W.; Zhao, M. Protective effect of taxifolin on H2O2-induced H9C2 cell pyroptosis. J. Cent. South Univ. Med. Sci. 2017, 42, 1367–1374. [Google Scholar]
Figure 1. Number of articles published on nailfold capillaroscopy (2023: Up to October).
Figure 1. Number of articles published on nailfold capillaroscopy (2023: Up to October).
Nutrients 16 01914 g001
Figure 2. Survey results for recently published papers including the use of nailfold capillaroscopy (1999 to 2023).
Figure 2. Survey results for recently published papers including the use of nailfold capillaroscopy (1999 to 2023).
Nutrients 16 01914 g002
Figure 3. Representative images of nailfold capillaries in healthy subjects [14]. From: Nakajima, T, et al., 2022 [14].
Figure 3. Representative images of nailfold capillaries in healthy subjects [14]. From: Nakajima, T, et al., 2022 [14].
Nutrients 16 01914 g003
Figure 4. Correlation of nailfold capillary morphology with lifestyle habits (cited from [15]). Upper: Dot plot showing loop length of nailfold capillaries negatively correlated with frequency of drinking alcohol. Dotted line: least-squares regression line. Lower: Schematic representation of correlation between nailfold capillary morphology and lifestyle habits. Cited from: Nakajima, T, et al. [15].
Figure 4. Correlation of nailfold capillary morphology with lifestyle habits (cited from [15]). Upper: Dot plot showing loop length of nailfold capillaries negatively correlated with frequency of drinking alcohol. Dotted line: least-squares regression line. Lower: Schematic representation of correlation between nailfold capillary morphology and lifestyle habits. Cited from: Nakajima, T, et al. [15].
Nutrients 16 01914 g004
Table 1. Normal capillaroscopic pattern in healthy subjects. (Summarized from [1,3,4,6,20]).
Table 1. Normal capillaroscopic pattern in healthy subjects. (Summarized from [1,3,4,6,20]).
ParameterDescription
Skin transparency Allows good visualization of the capillaries
Subpapillary venous plexusVisible in up to 30% of healthy individuals
General viewHomogeneously sized, regularly arranged
Capillary orientationStraight, parallel, usually perpendicular to the nailfold
Capillary densityMore than 7 capillaries per mm of nailfold
Capillary morphologyInverted “U”, hairpin shape, but also tortuous and/or crossing capillaries (nonspecific variations)
Capillary lengthLess than 300 μm
Capillary diameterLess than 20 μm for each loop (afferent, apical, efferent)
Pericapillary edemaAbsent
HemorrhagesAbsent (occasionally observed after microtrauma)
Giant capillariesAbsent
NeoangiogenesisAbsent
Blood flow characteristicsDynamic, no stasis
After Smith, V., et al. [1]; Dima, A., et al. [3]; Cutolo, M. [4]; Chojnowski, M.M., et al. [6]; and Kayser, C., et al. [20].
Table 2. Summary of nailfold morphology as observed by capillaroscopy (NFC) in normal healthy subjects [12,21,23,25].
Table 2. Summary of nailfold morphology as observed by capillaroscopy (NFC) in normal healthy subjects [12,21,23,25].
PublicationNFC Morphology
Ingegnoli, F., et al., 2013 [23] Based on a cluster analysis, three major “normal” morphologic capillaroscopic patterns were recognized: (1) the “normal” pattern, with mainly 2 to 5 U-shaped loops/mm and ≤2 tortuous loops/mm; (2) the “perfect normal” pattern with ≥5 U-shaped loops/mm; and (3) the “unusual normal” with at least 1 meandering or bushy loop, or at least 1 microhemorrhage, or with ≥5 crossed loops/mm. Regarding loop measurements, the majority of subjects had a median of 7 capillaries/mm with a median length of 198 μm.
Faggioli, P., et al., 2015 [25]Under physiological conditions the normal pattern is characterized by: (1) the orderly arrangement of capillaries to comb; (2) density of 9–13 μm (maximum 3 per dermal papilla); (3) 6–9 µm diameter afferent branch, efferent branch 8–21 µm (>50 µm: megacapillaries); (4) length 200–500 µm.
Tavakol, M.E., et al., 2015 [21]Nailfold capillary density appears to be similar in healthy adults and healthy children across Europe. European authors found the mean capillary density in healthy children to be in the range of 5–7.3 compared to 7.3–10.3 in healthy adults. Brazilian authors showed slightly higher capillary counts, ranging from 6–7.3 capillaries per millimeter in children and 9.11–10.1 capillaries per millimeter in adults.
Emrani, Z., et al., 2017 [12]The density of finger capillaries in healthy control subjects were summarized by collecting 17 articles published from 1990 to 2016 as follows. The mean capillary density was 8.45 ± 1.32/mm for individuals aged 40 or less and 8.71 ± 1.40 for individuals older than 40 years of age in healthy subjects *. Mean capillary densities in healthy males and females were found to be 8.83 ± 1.50 and 8.60 ± 1.26/mm, respectively. **
* Ingegnoli, F., Herrick, A.L., 2013 [27]. ** Hoerth, C., et al., 2012 [28].
Table 4. Number of fingertip capillary vessels measured 3 months after ingestion of LPSp supplement [16].
Table 4. Number of fingertip capillary vessels measured 3 months after ingestion of LPSp supplement [16].
Control (n = 26)LPSp Supplement (n = 26)
Months (M)0 M+3 M0 M+3 M
Per field4.92 ± 0.304.42 ± 0.254.65 ± 0.255.12 ± 0.27 *
Relative value1.0 ± 0.01.057 ± 0.171.0 ± 0.01.201 ± 0.10
Nailfold capillaroscopy was performed in the area near the lunula of the left ring finger. * Control +3 M vs. LPSp supplement +3 M, p < 0.05 by Mann–Whitney U test. From: Nakata, Y., et al. [16].
Table 5. Parallel relationship of nailfold capillaroscopy (NFC) data and peripheral artery disease (PAD)-relating conditions.
Table 5. Parallel relationship of nailfold capillaroscopy (NFC) data and peripheral artery disease (PAD)-relating conditions.
Authors and Published YearTitle and Description
<1>
Lundwall, K., et al., 2015
Paricalcitol, Microvascular and Endothelial Function in Non-Diabetic Chronic Kidney Disease: A Randomized Trial
[42]Endothelial function declined significantly over 3 months in patients with moderate CKD, and this decline was ameliorated by vitamin D receptor activator treatment, possibly through increased capillary blood flow.
<2>
Maranhao, P.A., et al., 2016
Dynamic Nailfold Videocapillaroscopy may be Used for Early Microvascular Dysfunction in Obesity
[43]The authors speculate that derangement of microvascular hemodynamics occurs before the presentation of the diagnosis of hypertension, diabetes, or other metabolic syndromes. Therefore, NFC is the most appropriate technique to precociously assess microvascular dysfunction in obesity.
<3>
Tian, J., et al., 2020
The Relationship Between Nailfold Microcirculation and Retinal Microcirculation in Healthy Subjects
[18]There was a direct relationship between nailfold capillary and retinal microcirculation. Therefore, abnormalities seen in NFC are associated with reduced retinal nerve fiber layer thickness and retinal vessel density.
<4>
Wijnand, J.G.J., et al., 2022
Naiflold Capillaroscopy in Patients with Peripheral Artery Disease of the Lower Limb (CAPAD Study)
[44]NFC abnormalities can be used as markers for inflammation and endothelial dysfunction in PAD.
<5>
Okabe, T., et al., 2023
Relationship between Nailfold Capillaroscopy Parameters and the Severity of Diabetic Retinopathy
[45]Alterations in NFC morphology, such as capillary shortening, may be closely correlated with the presence of diabetic retinopathy (DR) and proliferative DR.
Table 6. List of authorized claims in the USA with direct or indirect impact on microcirculation.
Table 6. List of authorized claims in the USA with direct or indirect impact on microcirculation.
Authorized Health ClaimsQualified Health Claims
Dietary saturated fatty acids and cholesterol and risk of coronary heart disease Whole grain foods with moderate fat content and risk of heart disease
Fruit, vegetables, and grain products that contain fiber *, particularly soluble fiber *, and risk of coronary heart diseaseSaturated fatty acids, cholesterol, and trans fatty acids, and reduced risk of heart disease
Soluble fiber * from certain foods and risk of coronary heart diseaseSubstitution of saturated fatty acids in diet for unsaturated fatty acids and reduced risk of heart disease
Soy protein and risk of coronary heart diseaseB vitamins and vascular disease
Plant sterol/stanol esters and risk of coronary heart diseaseNuts and heart disease
Walnuts and heart disease
Raposo, A., et al., 2021 [38]Omega 3 fatty acids and coronary heart disease
Monounsaturated fatty acids from olive oil and coronary heart disease
Unsaturated fatty acids from canola oil and reduced risk of coronary heart disease
* Fiber = dietary fiberCorn oil and corn oil-containing products and a reduced risk of heart disease
Table 7. List of nonauthorized claims in the EU with the word microcirculation [38].
Table 7. List of nonauthorized claims in the EU with the word microcirculation [38].
Nutrients, Substance, Food, or Food CategoryClaim[Ref] = Year
Dry isoflavones soy extract Acts on hair bulbs to support hair growth. Prevents hair from premature aging via antioxidant properties and microcirculation. [65] = 2011
Niacin (B Vitamin)Activates scalp microcirculation.[66] = 2009
BioflavonoidsIt has a positive effect on microcirculatory tropism by favoring the processes that protect small venous vessels. It protects the body from the harmful action of free radicals and the skin from ultraviolet rays.[67] = 2011
Vitamin E acetate (D,L alpha tocopherol acetate)It supports microcirculation and scalp oxygenation.[68] = 2010
OPC Plus, containing 40 mg oligomeric procyanidins (OPC) and 40 mg berry blend per capsuleOPC Plus has been shown to increase microcirculation and may, therefore, reduce the risk of chronic venous insufficiency.[69] = 2020
Table 8. Summary of protective effects of (−)-epicatechin and (+)-taxifolin and/or (−)-taxifolin on cardiovascular diseases in animal models [107].
Table 8. Summary of protective effects of (−)-epicatechin and (+)-taxifolin and/or (−)-taxifolin on cardiovascular diseases in animal models [107].
Biological Effects(−)-Epicatechin(+)-Taxifolin and/or (−)-Taxifolin
Vascular[115,116,117,118,119,120,121,122][123]
Cardioprotective[124,125,126][127,128]
Antiinflammatory[129,130,131][132,133]
Antiaggregatory, antithrombotic, or anticoagulant[115,134,135][136,137,138,139]
Table 9. Summary of anti-oxidative and anti-inflammatory effects of (−)-epicatechin and (+)-taxifolin and/or (−)-taxifolin on endothelial function [107].
Table 9. Summary of anti-oxidative and anti-inflammatory effects of (−)-epicatechin and (+)-taxifolin and/or (−)-taxifolin on endothelial function [107].
Cellular and Molecular Mechanisms(−)-Epicatechin(+)-Taxifolin and/or (−)-Taxifolin
ROS scavenging[140,141][142]
Activation of antioxidant enzymes (SOD, CAT, GPx)[143,144][128,145]
Elevation of endothelial NO[115,119,143,146,147][123]
NF-kB reduction[130,148,149][150]
Inflammasome reductionno[151,152]
ROS: reactive oxygen species; SOD: superoxide dismutase; CAT: catalase; GPx: Glutathione peroxidase; NO: nitric oxide.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Komai, M.; Takeno, D.; Fujii, C.; Nakano, J.; Ohsaki, Y.; Shirakawa, H. Nailfold Capillaroscopy: A Comprehensive Review on Its Usefulness in Both Clinical Diagnosis and Improving Unhealthy Dietary Lifestyles. Nutrients 2024, 16, 1914. https://doi.org/10.3390/nu16121914

AMA Style

Komai M, Takeno D, Fujii C, Nakano J, Ohsaki Y, Shirakawa H. Nailfold Capillaroscopy: A Comprehensive Review on Its Usefulness in Both Clinical Diagnosis and Improving Unhealthy Dietary Lifestyles. Nutrients. 2024; 16(12):1914. https://doi.org/10.3390/nu16121914

Chicago/Turabian Style

Komai, Michio, Dan Takeno, Chiharu Fujii, Joe Nakano, Yusuke Ohsaki, and Hitoshi Shirakawa. 2024. "Nailfold Capillaroscopy: A Comprehensive Review on Its Usefulness in Both Clinical Diagnosis and Improving Unhealthy Dietary Lifestyles" Nutrients 16, no. 12: 1914. https://doi.org/10.3390/nu16121914

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop